TY - JOUR
T1 - Acute flaccid paralysis (AFP) surveillance: challenges and opportunities from 18 years’ experience, Spain, 1998 to 2015
AU - Masa-Calles, Josefa
AU - Torner, Nuria
AU - López-Perea, Noemí
AU - de Mier, María de Viarce Torres
AU - Fernández-Martínez, Beatriz
AU - Cabrerizo, María
AU - Gallardo-García, Virtudes
AU - Malo, Carmen
AU - Margolles, Mario
AU - Portell, Margarita
AU - Abadía, Natividad
AU - Blasco, Aniceto
AU - García-Hernández, Sara
AU - Marcos, Henar
AU - Rabella, Núria
AU - Marín, Celia
AU - Fuentes, Amelia
AU - Losada, Isabel
AU - Gutiérrez, Juan García
AU - Nieto, Alba
AU - Ortúzar, Visitación García
AU - Cenoz, Manuel García
AU - Arteagoitia, José María
AU - Martínez, Ángela Blanco
AU - Rivas, Ana
AU - Castrillejo, Daniel
AU - Sanbonmatsu, S.
AU - Navarro, J. M.
AU - Omeñaca, M.
AU - Pérez-González, C.
AU - del Cuerpo, M.
AU - Guiral, S.
AU - Ramos, J. M.
AU - García-Fulgueiras, A.
AU - Barricarte, A.
AU - Martínez Ochoa, E.
PY - 2018/11/22
Y1 - 2018/11/22
N2 - © 2018, European Centre for Disease Prevention and Control (ECDC). All rights reserved. Acute flaccid paralysis (AFP) surveillance is key for global polio eradication. It allows detecting poliovirus (PV) reintroductions from endemic countries. This study describes AFP surveillance in Spain from 1998 to 2015. During this time, 678 AFP cases were reported to the Spanish National Surveillance Network. The mean notification rate was 0.58 AFP cases/100,000 population under 15 years old (range: 0.45/100,000– 0.78/100,000). Two periods (P) are described: P1 (1998–2006) with the AFP notification rate ranging from 0.66/100,000 to 0.78/100,000, peaking in 2001 (0.84/100,000); and P2 (2007–2015) when the AFP rate ranged from 0.43/100,000 to 0.57/100,000, with the lowest rate in 2009 (0.31/100,000). No poliomyelitis cases were caused by wild PV infections, although two Sabin-like PVs and one imported vaccine-derived PV-2 were detected. Overall, 23 (3.4%) cases met the hot case definition. Most cases were clinically diagnosed with Guillain–Barré syndrome (76.9%; 504/655). The adequate stool collection rate ranged from 33.3% (7/21) to 72.5% (29/40). The annual proportion of AFP cases with non-polio enterovirus findings varied widely across the study period. AFP surveillance with laboratory testing for non-polio enteroviruses must be maintained and enhanced both to monitor polio eradication and to establish sensitive surveillance for prompt detection of other enteroviruses causing serious symptoms.
AB - © 2018, European Centre for Disease Prevention and Control (ECDC). All rights reserved. Acute flaccid paralysis (AFP) surveillance is key for global polio eradication. It allows detecting poliovirus (PV) reintroductions from endemic countries. This study describes AFP surveillance in Spain from 1998 to 2015. During this time, 678 AFP cases were reported to the Spanish National Surveillance Network. The mean notification rate was 0.58 AFP cases/100,000 population under 15 years old (range: 0.45/100,000– 0.78/100,000). Two periods (P) are described: P1 (1998–2006) with the AFP notification rate ranging from 0.66/100,000 to 0.78/100,000, peaking in 2001 (0.84/100,000); and P2 (2007–2015) when the AFP rate ranged from 0.43/100,000 to 0.57/100,000, with the lowest rate in 2009 (0.31/100,000). No poliomyelitis cases were caused by wild PV infections, although two Sabin-like PVs and one imported vaccine-derived PV-2 were detected. Overall, 23 (3.4%) cases met the hot case definition. Most cases were clinically diagnosed with Guillain–Barré syndrome (76.9%; 504/655). The adequate stool collection rate ranged from 33.3% (7/21) to 72.5% (29/40). The annual proportion of AFP cases with non-polio enterovirus findings varied widely across the study period. AFP surveillance with laboratory testing for non-polio enteroviruses must be maintained and enhanced both to monitor polio eradication and to establish sensitive surveillance for prompt detection of other enteroviruses causing serious symptoms.
UR - https://www.scopus.com/pages/publications/85057291646
U2 - 10.2807/1560-7917.ES.2018.23.47.1700423
DO - 10.2807/1560-7917.ES.2018.23.47.1700423
M3 - Article
C2 - 30482263
SN - 1025-496X
VL - 23
JO - Eurosurveillance
JF - Eurosurveillance
M1 - 1700423
ER -